Status:
UNKNOWN
Anti-inflammatory Effect of Atorvastatin in Atherosclerotic Plaques Assessed by FDG-PET Imaging
Lead Sponsor:
National Defense Medical College, Japan
Conditions:
Atherosclerosis
Inflammation
Eligibility:
All Genders
18-80 years
Phase:
PHASE4
Brief Summary
The purpose of this study is to determine whether HMG-CoA reductase inhibitor, atorvastatin attenuates inflammation in atherosclerotic plaques detected by 18F-fluorodeoxyglucose(FDG) PET.
Eligibility Criteria
Inclusion
- Subjects with accumulation of FDG-PET in carotid artery or aorta
Exclusion
- LDL cholesterol level (calculated by using Friedewald formula) higher than 180 mg/dl or less than 120 mg/dl
- subjects currently taking HMG CoA-reductase (Statins) or fibrates
- symptomatic coronary artery diseases
- symptomatic cerebrovascular diseases
- subjects suffered from myocardial infarction or stroke within 6 months
- subjects underwent percutaneous vascular interventions or vascular operations within 6 months
- diabetic patients with poor glycemic control (HbA1c\>8.5)
- hypertensive patients with poor blood pressure control
- subjects with neoplasms
- subjects with systemic inflammatory diseases
Key Trial Info
Start Date :
June 1 2009
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
December 1 2013
Estimated Enrollment :
30 Patients enrolled
Trial Details
Trial ID
NCT00920101
Start Date
June 1 2009
End Date
December 1 2013
Last Update
March 12 2013
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
National Defense medical College
Tokotozawa, Saitama, Japan, 359-8513